Background and aims Previous studies have reported inconsistent findings that proton pump inhibitors (PPIs) therapy might increase the risk of hip fracture. We investigated the association between PPIs therapy and hip fracture by a systematic review and meta-analysis.
We investigated the association between PPIs therapy and hip fracture by a systematic review and meta-analysis.
Methods We systematically searched PubMed, EMBASE, and the Cochrane Library. We included studies assessing the effects of PPIs on hip fracture. Data from the studies about odds ratio and 95% confidence interval were gathered and summarized.
Results Seven studies met the inclusion criteria. PPIs therapy was associated with a statistically significant increase of hip fracture risk (pooled odds ratio = 1.24; 95% confidence interval: 1.15-1.34; P < 0.00001) under a random model. Meanwhile, we found that the effect of PPIs on hip fracture differs in different duration groups.
Introduction
Proton pump inhibitors (PPIs) are widely prescribed medications with an excellent short-term safety profile in clinical practice since their introduction in the late 1980s. They are used for the treatment of various disorders, ranging from dyspepsia to gastroesophageal reflux disease, with a mechanism to inhibit the gastric acid secretion [1] . Countless individuals have benefited from them on a continuous or long-term basis. In Finland, 22% of the nursing home residents were administrated PPIs regularly [2] .
Similar to any other medication, PPIs have unexpected potential adverse consequences and benefits. It has been reported that PPIs may lead to headache, nausea, diarrhea, abdominal pain, community-acquired pneumonia, acute interstitial nephritis, and anaphylactic reactions [3] [4] [5] [6] [7] . Recently, several studies from a variety of data sources have suggested that there might be a relationship between PPIs and fracture, especially hip fracture. The US Food and Drug Administration has also alerted consumers and healthcare providers regarding the potential increased risk of hip, wrist, and spine fractures associated with high doses or long-term use of PPIs [8] .
Fracture is a common injury around the world. It is estimated that the number of people with fractures worldwide was approximately 56 million in 2000, and approximately 9 million new osteoporotic fractures occur each year [9] . The global number of hip fracture is estimated to be 7-21 million by 2050 [10] . Morbidity and mortality are associated with fracture. Mortality associated with hip fracture is approximately 5-10% after 1 month and 20% during the first year [10] [11] [12] . High prevalence of fracture leads to high health expenditures, lost productivity, and lower quality of life of the victims. Hence, it would be of substantial importance to identify the potential risk factors of fracture.
An acidic environment in the gastrointestinal tract facilitates the release of ionized calcium from insoluble calcium salts [13] . The presence of gastric acid facilitates the absorption of dietary calcium. It has been reported that the use of PPIs decreases calcium absorption in the stomach, which increases the risk for hip fracture. Conversely, PPIs may also reduce bone resorption through proton pump inhibition of osteoclastic cells, which may decrease the risk of hip fracture [14] . Limited animal and human studies have shown that PPIs therapy may decrease insoluble calcium absorption or bone density [15, 16] .
A number of studies have been conducted to assess the effect of PPIs on hip fracture [17] [18] [19] . However, studies investigating the association between PPIs and hip fracture have reported conflicting results. Some studies suggested there is an association between them, whereas others argued that PPIs had no effect on hip fracture. To address this uncertainty, we performed a systematic review and meta-analysis to determine whether the association between PPIs and hip fracture exists quantitatively.
Methods
We conducted this study following the checklist for metaanalyses of observational studies (Meta-analysis Of Observational Studies in Epidemiology) proposed by Stroup et al. [20] .
Data collection
Related studies in all languages were identified by searching multiple electronic databases including: PubMed (from 1976 to June 2010), EMBASE (from 1966 to June 2010), and the Cochrane Library (no date restriction). The search was carried out in June 2010. We restricted the search to studies on human participants, using the following terms: proton pump inhibitors, proton pump inhibitor, PPIs, omeprazole, lansoprazole, pantoprazole, rabeprazole, leminoprazole, esomeprazole, dexlansoprazole, and fracture.
Study selection
We assessed the quality of included studies by the Strengthening the Reporting of Observational Studies in Epidemiology checklist, taking 22 items as gauge. Only those studies of high quality could be included in a metaanalysis to reach a credible conclusion.
To be included in this systematic review and metaanalysis, trials should have compared hip fracture between PPI users and non-PPI users. Cohort study, case-control study, or similar designs were included. The reviewers extracted the data independently using standardized data collection forms. The following information was collected from the identified trials: publication information (title, first author's name, year), study characteristics (study design, study region, endpoint index, regimen details), characteristics of study population (sample size, age), and outcome for the whole study populations. The information about fracture, exposure ascertainment, and control variables was shown in Table 1 .
The literature search and data extraction were undertaken independently by two investigators (X.Y., Y.Q.) to determine whether they met the criteria for inclusion. When there was discrepancy between the two investigators, the two investigators discussed with another investigator (J.H.) to make a consensus.
Statistical analysis
Odds ratio (OR) was used as a measurement for the relationship between PPIs therapy and the risk of hip fracture. Differences observed between groups were expressed as OR with 95% confidence interval (CI). For cohort studies or prospective studies, relative risk and hazard ratio were used as a surrogate measure of the corresponding OR. As the incidence of hip fracture is low, the OR approximates the relative risk and hazard ratio [27] . Individual OR and 95% CI were extracted or calculated initially, and then log (OR) and its corresponding standard error were estimated for pooling. Statistical heterogeneity between trials was evaluated by w 2 test and I 2 statistic, and was considered to be present when the P value is less than 0.1. In the presence of statistical heterogeneity, a random-effect model was used for the analysis. In the absence of statistically significant heterogeneity, the OR by the fixed-effect model is calculated. Subgroup analyses were conducted to compare the effect in different subtypes, such as region, dosage, and duration.
We assessed the presence of publication bias by examining funnel plot and by calculating the Egger coefficient. All statistical analyses were conducted with the freeware Review Manager (version 5.0 for Windows, Cochrane Collaboration, Oxford, UK, 2010) and STATA 11.0 (Stata Corporation, Lakeway, Texas, USA).
Results

Results of search strategy
The literature search yielded 109 articles and all were reviewed in detail using the search strategy summarized in Fig. 1 . Thirteen studies were reviewed as potentially relevant studies, of which six trials were excluded Table 1 Information about fracture, exposure ascertainment, and control variables according to the exclusion criteria. The remaining seven studies met the inclusion criteria [14, [21] [22] [23] 25, 26, 28] .
The characteristics of the original studies were presented in Table 2 . All these studies were conducted in North America and Europe. In a study conducted by Yu et al. [25] , two separate databases, Osteoporotic Fractures in Men Study and the Study of Osteoporotic Fractures for women were studied. We took them as two independent studies and eight studies in total were included in this study. Five studies mentioned the dosage of PPIs and only five studies mentioned about the medication duration. Together, 1 166 096 participants were included in this meta-analysis.
In a study conducted by Targownik et al. [28] , patients were divided into several groups according to the exposure time. We just selected the adjusted OR from the shortest exposure time group with time greater than 1 year. In a study conducted by Pouwels et al. [14] , data from the patients, who currently used PPIs, were extracted.
Effect of proton pump inhibitors on hip fracture
From the eight studies, meta-analysis showed a significantly increased risk of hip fracture for patients who received PPIs compared with non-PPIs (pooled OR = 1.24; 95% CI: 1.15-1.34; P < 0.00001) under a random model (w 2 = 12.56; I 2 = 44%; P = 0.08; Fig. 2 ). There was no evidence of publication bias in our study and the Egger coefficient was also calculated (Egger = -1.552; P = 0.064).
Region
All the included studies were conducted in Europe and North America. We conducted a subgroup analysis for these two regions. Three studies conducted in Europe revealed an association between PPIs therapy and hip fracture (pooled OR = 1.29; 95% CI: 1.14-1.45; P < 0.00001) under a random model. Another five studies carried out in North America also demonstrated such association (pooled OR = 1.26; 95% CI: 1.18-1.34; P < 0.00001) under a fixed model (Fig. 3) . No significant Potentially relevant citations identified and screened for retrieval (n = 109)
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interactions were found in different regions (interaction P = 0.735).
Duration
Whether the effect of long duration use of PPIs on hip fracture existed was considered in several studies, but different durations were analyzed in different studies, which were summarized in Table 2 . We performed a subgroup analysis according to three durations: short duration (< 1 year), medium duration (1-3 years), and long duration (> 3 years). We extracted the data from the original studies first and then combined the data together. Some studies did not Pouwels et al. [14] Corley et al. [21] Gray et al. [22] De Vries et al. [23] Targownik et al. [28] Yu _SOF et al. [25] Yu _MrOS et al. [25] Vestergaard et al. [26] give an exact effect for our expected duration. For example, in the study conducted by Pouwel et al. [14] , they just analyzed the duration of more than 3 months and 4-12 months. To get the duration of more than 1 year, we first combined these two durations and got the whole effect on hip fracture into a duration of less than 1 year. In addition, we performed a subgroup analysis of a long-term duration for a further 6 years. Pouwels et al. [14] De Vries et al. [21] Vestergaard et al. [26] Subtotal North America
Gray et al. [22] Corley et al. [21] Targownik et al. [28] Yu _SOF et al. [25] Yu _MrOS et al. [25] Subtotal Duration <1 year >3 years
1-3 years
Pouwels et al. [14] Gray et al. [22] Corley et al. [21] De Vries et al. [23] Pouwels et al. [14] Gray et al. [22] Subtotal De Vries F [23] Pouwels et al. [14] Gray et al. [22] Targownik et al. [28] Subtotal De Vries et al. [23] >6 years Corley et al. [21] Targownik et al. [28] Our analysis indicated that there was association between PPIs and hip fracture in the short-duration group (pooled OR = 1.25; 95% CI: 1.20-1.31; P < 0.0001) and mediumduration group (pooled OR = 1.19; 95% CI: 1.05-1.39; P = 0.006). No association was observed in the longduration group (pooled OR = 1.11; 95% CI: 0.97-1.27; P = 0.14). However, association was observed in the group of duration greater than 6 years (pooled OR = 1.40; 95% CI: 1.28-1.52; P < 0.0001).
Discussion
In our study, eight studies met the inclusion criteria. We observed that PPIs therapy was associated with the risk of hip fracture (pooled OR = 1.24; 95% CI: 1.15-1.34; P < 0.00001) under a random model. Different effects on hip fracture in the subgroup analysis did not support a causal relationship between PPIs and hip fracture. If there is a really causal association between PPIs and hip fracture, the effect might increase with the duration. Whether the risk exists warrants further investigation.
The mechanism by which extended use of PPIs increases the risk of hip fracture remains unknown. In-vitro calcium carbonate dissolution and disintegration is dependent on low pH. O'Connell et al. [16] found that during omeprazole (20 mg) therapy, significantly decreased absorption of calcium was taken by elderly women (Z 65 years) after an overnight fast and on an empty stomach. However, a study conducted by SerfatyLacrosniere et al. [30] demonstrated that moderate hypochlorhydria resulting from short-term omeprazole treatment does not substantially lead to calcium deficiencies due to mineral malabsorption. PPIs also inhibit the osteoclastic proton transport system, but the affinity for the osteoclast-type proton pump is much weaker than gastric pump [31] . Further studies about the mechanism are requested.
Other factors may contribute to the incidence of hip fracture, a strategy of stratification of sex was performed in the study by Pouwels et al. [14] . The risk of fracture was statistically significantly higher among current PPI users who were men (OR = 1.57; 95% CI: 1.16-2.12) compared with women (OR = 1.12; 95% CI: 0.94-1.32; [14] ). In a recent study by Targownik et al. [24] , they found that the association between PPI use and hip fracture is probably related to factors independent of osteoporosis. Calcium supplement tended to be another contributor to hip fracture. An increased hip fracture incidence was observed among male PPI users without calcium supplement, but not among male PPI users with calcium supplement [25] .
In the process of study selection, we observed that the studies conducted by Kaye and Jick [32] , Yang et al. [33] , and De Vries et al. [23] came from the same database UK General Practice Research Database (GPRD). Perhaps, these three studies largely analyzed the same study population. We just chose the GPRD study with the largest and most recent version of the database. We also found that the use of International Classification of Diseases (ICD) codes and relying on pharmacy data to capture data might lead to information bias in the original studies. The way of adjudicated diagnosis and patient interview is better in reducing the information bias.
We noticed that even the same database GPRD used by three separate studies, resulted in different conclusions.
A negative association was observed in the Kaye and Jick [32] study and a positive association was obtained in studies conducted by Yang et al. [33] and De Vries et al. [23] . Selection bias could explain the difference [29] . Kaye just selected the patients without major risk factors into their study, which might suggest there was a possibility that other risk factors contribute to the hip fracture. In addition, the study by De Vries et al. [23] found a small positive association but the authors emphasized that 'there was inverse association between duration use of acid-suppressive medications and fracture risk, which does not support adverse effects on the bone'.
Our study has some limitations that deserve further discussion. First and foremost, this meta-analysis used data from epidemiological studies (case-control study, cohort study, and similar designs), which were unable to control three major potential confounders: alcohol use (none of the studies, patients tend to lie about this also to their general practitioner), smoking status, and BMI. Second, we just extracted part of data from two original studies, as there were no data about the total effect, which might distort the intrinsic relationship. Third, the included studies were conducted only in Europe and North America, no evidence was found in other continents. Fourth, we only searched for the existing publications concerning PPIs and fractures; this would lead to inclusion of mere epidemiological studies of drug safety. The original randomized clinical trials reporting efficacy and adverse effects of PPIs should be explored and reported. However, we did not contact the drug companies or original researchers to get the unreported adverse events. Cohort studies, case-control studies, and cross-sectional studies were included in our study to investigate the relationship between PPIs and hip fracture. In fact, the evidence supported by these designs was less strong than the randomized controlled trials. These studies show only association, and causal relationship is impossible to conclude from these studies. The conclusion drawn from these studies should be explained cautiously.
Due to the limitation of meta-analysis, further studies are required to determine the clinical importance of our findings. Specifically designed studies are needed to investigate the effect of PPIs on hip fracture. Long-term, well-designed, matched cohort study or randomized controlled trials (RCTs) conducted to explicitly assess the incidence of osteoporotic fractures, would be the preferred experimental approach [34] . RCT, such as those conducted in clinical trials, needs high expenditure and practitioners in this area. It requires several rigorous processes including participant enrolment, randomization, and so on. It is suggested that pharmaceutical companies manufacturing PPIs should take the responsibility to conduct such RCT.
In conclusion, this meta-analysis shows that PPIs therapy perhaps has the potential risk of increasing hip fracture. Different effects on hip fracture in the subgroup analysis do not support the causal relationship between PPIs and hip fracture. Whether the risk exists warrants further investigation.
